152 related articles for article (PubMed ID: 33760215)
1. Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1.
Luo J; Jin Y; Li M; Dong L
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760215
[TBL] [Abstract][Full Text] [Related]
2. miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN.
Wang C; Wang S; Ma F; Zhang W
Mol Med Rep; 2018 Nov; 18(5):4563-4570. PubMed ID: 30221716
[TBL] [Abstract][Full Text] [Related]
3. miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2.
Du H; Bao Y; Liu C; Zhong A; Niu Y; Tang X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300085
[TBL] [Abstract][Full Text] [Related]
4. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
Luo S; Shen M; Chen H; Li W; Chen C
Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838
[TBL] [Abstract][Full Text] [Related]
5. miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells.
Lin C; Xie L; Lu Y; Hu Z; Chang J
Int J Mol Med; 2018 Apr; 41(4):2050-2058. PubMed ID: 29328427
[TBL] [Abstract][Full Text] [Related]
6. miR‑379‑5p inhibits cell proliferation and promotes cell apoptosis in non‑small cell lung cancer by targeting β‑arrestin‑1.
Jiang Y; Zhu P; Gao Y; Wang A
Mol Med Rep; 2020 Dec; 22(6):4499-4508. PubMed ID: 33173959
[TBL] [Abstract][Full Text] [Related]
7. miR‑497 suppresses malignant phenotype in non‑small cell lung cancer via targeting KDR.
Xia Y; Hu C; Lian L; Hui K; Wang L; Qiao Y; Liu L; Liang L; Jiang X
Oncol Rep; 2019 Jul; 42(1):443-452. PubMed ID: 31115562
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
Wang W; Zhao M; Cui L; Ren Y; Zhang J; Chen J; Jia L; Zhang J; Yang J; Chen G; Ashby CR; Wu C; Chen ZS; Wang L
Mol Cancer; 2020 Sep; 19(1):134. PubMed ID: 32878625
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1.
Wang S; Sun H; Zhan X; Wang Q
Int J Mol Med; 2020 Jan; 45(1):33-44. PubMed ID: 31746372
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
12. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer.
Li K; Yuan C
Int J Mol Med; 2020 Sep; 46(3):1013-1028. PubMed ID: 32582959
[TBL] [Abstract][Full Text] [Related]
14. miR‑491‑3p functions as a tumor suppressor in non‑small cell lung cancer by targeting fibroblast growth factor 5.
Zhang G; Zheng H; Wang L
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35866594
[TBL] [Abstract][Full Text] [Related]
15. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
16. Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression.
Li GJ; Zhao GQ; Yang JP; Zhou YC; Yang KY; Lei YJ; Huang YC
Oncol Rep; 2017 Jun; 37(6):3475-3483. PubMed ID: 28498474
[TBL] [Abstract][Full Text] [Related]
17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance and Tumor-Suppressive Function of miR-516b in Nonsmall Cell Lung Cancer.
Zhu J; Zhang Y; Yang X; Jin L
Cancer Biother Radiopharm; 2017 May; 32(4):115-123. PubMed ID: 28514208
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
20. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
